Murray J Goodman MD
Hand Surgery
Clinical Instructor in Orthopedic Surgery, Brigham and Women's Hospital
Join to View Full Profile
4300 S US Hwy 1Ste 203-292Jupiter, FL 33477
Dr. Goodman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Orthopaedic Surgery, 1976 - 1979
Beth Israel Deaconess Medical CenterResidency, Surgery, 1972 - 1975
Perelman School of Medicine at the University of PennsylvaniaClass of 1972
Certifications & Licensure
MA State Medical License 1973 - 2027
CA State Medical License 1978 - 2026
FL State Medical License 2017 - 2026
WA State Medical License 2016 - 2023
American Board of Orthopaedic Surgery Orthopaedic Surgery
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- 2 citationsConflicts of interest with the hand surgeon's relationship with industry.Jeanne L. DelSignore, Murray J. Goodman
The Journal of Hand Surgery. 2012-01-01 - 3 citationsConformational analysis of potent sweet taste ligands by nuclear magnetic resonance, computer simulations and X-ray diffraction studies.Ralph-Heiko Mattern, Yusuke Amino, Ettore Benedetti, Murray Goodman
The Journal of Peptide Research. 2009-01-12 - 8 citations14-membered cyclic opioids related to dermorphin and their partially retro-inverso modified analogues. I. Synthesis and biological activity.Odile E. Said-Nejad, Eduard R. Felder, Dale F. Mierke, Toshtmasa Yamazaki, Peter W. Schiller
International Journal of Peptide and Protein Research. 2009-01-12
Press Mentions
Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 InhibitorsDecember 13th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
